Browse the evidence

People with overweight or obesity and metabolic comorbidities experience significantly higher work impairment (activity impairment and presenteeism) compared to those without such comorbidities.

If you have overweight or obesity and metabolic conditions like diabetes, your work productivity is likely significantly lower than someone with the same BMI but no metabolic issues. This is due to reduced activity levels and effectiveness at work, which are key targets for treatment.

Current interventions, including calorie restriction, physical activity, and pharmacological treatment, show promise in combating obesity, but long-term efficacy and safety need further establishment.

There is no single magic bullet for obesity. The most promising approach combines lifestyle changes (diet and exercise) with medical treatments if necessary. However, long-term success is not guaranteed, and ongoing management is likely required.

Laparoscopic bariatric surgery (specifically RYGB and SG) produces greater weight loss and higher rates of type 2 diabetes remission compared to non-surgical interventions, including lifestyle changes and GLP-1 receptor agonists.

For severe obesity, laparoscopic surgery (like gastric bypass or sleeve) currently offers the highest chance of significant, sustained weight loss (20-30%) and diabetes remission compared to drugs or diet alone. However, it requires lifelong vitamin supplementation and carries surgical risks. New medications (GLP-1s) are closing the gap, offering 15-20% loss, but surgery remains the most effective option for those who qualify.

High-intensity physical activity significantly reduces the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with stable obesity, whereas high-intensity activity combined with significant net weight gain (>20 kg) paradoxically increases MASLD risk compared to lower intensity activities.

If you have stable obesity, high-intensity exercise (over 1200 MET min/week) is significantly better for your liver than low-intensity activity. However, if you are gaining a lot of weight (>20kg) over time, high-intensity exercise might actually increase your liver disease risk compared to moderate or low intensity. Focus on maintaining stable weight with high intensity, or use moderate intensity if you are struggling with weight gain.

In asymptomatic individuals with Type 2 Diabetes (T2D) and obesity, alternative cardiopulmonary exercise testing (CPET) indices—specifically oxygen uptake recovery, heart rate recovery, and oxygen uptake at the ventilatory threshold—are significantly impaired compared to healthy controls and are independently associated with markers of subclinical cardiovascular dysfunction (aortic stiffness, diastolic dysfunction, and microvascular impairment).

If you have Type 2 Diabetes and are overweight, standard fitness tests might not tell the whole story about your heart health. Specific recovery metrics after exercise (how fast your oxygen use and heart rate drop) and your ventilatory threshold are better indicators of early heart stress. These markers can help identify who is at risk for developing heart failure before symptoms appear, allowing for earlier lifestyle or medical intervention.

Combining 16:8 time-restricted eating (TRE) with structured exercise yields modest additional reductions in body weight and fat mass compared to exercise alone.

If you already exercise regularly, adding a 16:8 time-restricted eating schedule (fasting for 16 hours, eating within 8 hours) may help you lose an extra 1-1.5 kg of body weight and about 1 kg of fat mass over 4-8 weeks compared to exercising without dietary timing restrictions. This benefit is modest but real, particularly if you perform aerobic exercise.

Probiotics (specifically Lactobacillus and Bifidobacterium strains) improve gastrointestinal health by modulating the immune system, enhancing epithelial barriers, and suppressing pathogen adhesion.

To support gut health, consider incorporating probiotic-rich foods or supplements containing Lactobacillus or Bifidobacterium strains. These microbes help maintain the gut barrier and support immune function. If you are immunocompromised, consult a doctor first to ensure the specific strain is safe for you.

Resistance training does not significantly improve appendicular skeletal muscle mass (ASM) or appendicular skeletal muscle mass index (ASMI) in older adults with sarcopenia.

Do not expect resistance training to significantly increase your muscle mass or muscle mass index if you have sarcopenia. The benefits you feel (strength, balance) are likely due to your nervous system working better, not your muscles getting bigger. This is still a positive outcome for function, even if the scale or tape measure doesn't change much.

Spirulina supplementation does not significantly reduce waist circumference in the general adult population, though it may benefit obese individuals over 40.

Do not expect Spirulina to significantly reduce waist circumference for the general population. However, if you are obese and over 40, taking ≥2g/day may help. Focus on its proven benefits for overall weight and body fat reduction instead.

Public health strategies targeting the obesogenic environment (e.g., SSB taxes, zoning, produce prescriptions) are necessary to support individual weight management efforts, as individual lifestyle advice is undermined by environmental factors.

Individual willpower is not enough in an environment designed to promote obesity. Support public health policies like sugar taxes, zoning for healthy food access, and produce prescription programs. These environmental changes make healthy choices easier and more affordable.

Long-term intermittent fasting (IF) protocols, particularly time-restricted eating (TRE) with short windows (e.g., 8 hours), are associated with increased cardiovascular disease (CVD) mortality and adverse cardiac structural changes, primarily mediated by lean mass loss, circadian misalignment, and reward-based poor dietary choices.

If you practice intermittent fasting, be aware that long-term use (especially with very short eating windows like 8 hours) may increase your risk of heart disease and mortality, particularly if you have existing heart conditions or genetic risks. The benefits seen in short-term studies (less than 12 weeks) do not necessarily translate to long-term health. Focus on preserving muscle mass, eating nutrient-dense foods, and consider combining fasting with exercise or switching to a Mediterranean diet for better long-term cardiovascular outcomes.

Endoscopic Bariatric Procedures (EBP), including intragastric balloon (IGB), aspiration therapy (AT), and primary obesity surgery endoluminal (POSE), are generally less effective than newer OMMs (semaglutide, tirzepatide) and have limited long-term data.

Endoscopic procedures (IGB, AT, POSE, ESG) offer moderate weight loss (3.8-12.8% TBWL) in the short term but are generally less effective than newer medications (semaglutide, tirzepatide) and lack long-term efficacy data. They may be considered for patients who are not candidates for surgery or high-dose medications, but they are not the most effective option for significant, sustained weight loss.

Geroscience aims to compress the period of morbidity by targeting the fundamental biological mechanisms of aging, rather than treating individual age-related diseases in isolation.

This paper outlines a research strategy, not a direct lifestyle intervention. However, the implication for an individual is that healthspan (the period of life spent in good health) is a distinct and measurable goal from lifespan. Supporting geroscience research involves advocating for and participating in studies that target fundamental aging processes (like cellular senescence or metabolic regulation) rather than just managing symptoms of single diseases as they appear.

Access to semaglutide 2.4 mg is significantly hindered by national shortages, high costs, and insurance coverage issues.

Secure insurance coverage early. Be aware of potential shortages and costs. Utilize patient assistance programs if out-of-pocket costs are prohibitive.

Dysbiosis (specifically reduced SCFA-producing bacteria and increased pro-inflammatory taxa) contributes to the pathogenesis of Type 2 Diabetes through mechanisms involving gut permeability, LPS-driven inflammation, and impaired insulin signaling.

Maintaining gut health through a fiber-rich diet may help manage blood sugar levels by reducing inflammation and improving insulin sensitivity. This is particularly relevant for those with or at risk for Type 2 Diabetes.

Training to failure does not produce a repeated bout effect (RBE) that mitigates longitudinal fatigue or recovery differences over an 8-week period.

Training to failure does not seem to 'protect' you from future fatigue or soreness over time. If you choose to train to failure, expect similar fatigue levels to submaximal training in the long run, but potentially lower strength gains.

Modifying structural and social determinants of health (SDOH), such as housing and economic stability, is a necessary lever for achieving health equity in obesity treatment, as individual-level interventions alone fail to address root causes of disparities.

To improve obesity outcomes for marginalized groups, interventions must go beyond diet and exercise advice. They need to address structural barriers like housing stability and income. Policy changes and community-level investments are essential to create equitable opportunities for health.

An altered enteric microbiome contributes to obesity by enhancing energy harvest from dietary roughage, modulating intestinal physiology to slow transit, and influencing the entero-insular axis and central nervous system to increase appetite and fat storage.

Your gut bacteria play a significant role in how much energy you get from food and how your body stores it. While diet and exercise remain important, understanding that your microbiome influences hunger, fat storage, and nutrient absorption can help explain why weight management is challenging. Strategies like targeted probiotics or dietary changes that support a healthy microbiome may offer additional support alongside traditional lifestyle changes.

Improvement in cellulite severity is not significantly correlated with changes in body weight or fat mass, indicating that local structural and metabolic-dermal interventions are primary drivers of cellulite reduction rather than systemic adiposity loss.

If you are trying to reduce cellulite, relying solely on weight loss or fat loss may not yield visible improvements in skin texture. This study suggests that combining systemic metabolic health (e.g., managing insulin/inflammation) with targeted local treatments (like specific topical formulations) is more effective for cellulite than weight loss alone. Focus on local tissue health and metabolic balance rather than just the scale.

In non-beta tissues (liver, kidney, skeletal muscle, adipose), the mitochondrial benefits of GLP-1RAs are likely a combination of direct receptor signaling and indirect systemic improvements such as weight loss and reduced inflammation.

While GLP-1 drugs improve mitochondrial health in organs like the liver and muscles, these benefits are partly due to the overall reduction in body weight and blood sugar. It is a combined effect of losing weight and the drug's direct action on cells.

Biliopancreatic Diversion (BPD) appears to be the most effective bariatric surgery for achieving T2DM remission and lowering HbA1c levels, although evidence is sparse due to limited study numbers.

Biliopancreatic Diversion (BPD) shows the strongest potential for reversing Type 2 Diabetes and significantly lowering HbA1c levels among all bariatric surgeries. However, because very few studies have evaluated it, its use is limited by concerns over surgical complexity and complications. It should be considered for patients with severe T2DM and obesity who are willing to accept higher surgical risks for the best chance of remission.

Combining protein supplementation with exercise does not provide a robust benefit for bone mineral content (BMC) or density (BMD) in middle-aged and older adults compared to exercise or protein alone.

If your goal is bone health, focus on consistent resistance or weight-bearing exercise and adequate protein intake separately. Adding extra protein supplements on top of your exercise routine does not currently show evidence of providing additional bone density benefits compared to doing just one of those things alone.

Dietary interventions (caloric restriction, high-fat, high protein-to-carbohydrate ratios, and specific micronutrients) administered during critical developmental windows (puberty, pregnancy, or lifetime) can induce transgenerational epigenetic modifications that protect offspring against environmental toxins.

To potentially protect future generations from environmental toxins, parents should consider adopting protective dietary patterns—such as high protein-to-carbohydrate ratios, caloric restriction, or specific micronutrient supplementation—during critical life stages like puberty, pregnancy, or throughout their lifetime. These dietary choices can induce epigenetic changes that may persist for multiple generations.

Age is the most significant factor for multimorbidity, with individuals over 60 years old having a 5.89 times higher likelihood of reporting two or more chronic diseases compared to those under 49.

As you age, the risk of developing multiple chronic conditions increases significantly. However, managing modifiable risk factors like blood pressure and weight can help mitigate this risk. Regular health screenings and adherence to medication for conditions like hypertension and diabetes are crucial for older adults to prevent multimorbidity.